| Belmont Manor Nursing Home, In | |
| 34 Agassiz Avenue, Belmont, Massachusetts 02478 | |
| (617) 489-1200 | |
| Name | Belmont Manor Nursing Home, In |
|---|---|
| Location | 34 Agassiz Avenue, Belmont, Massachusetts |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 156 |
| Occupancy Rate | 90.64% |
| Medicare ID (CCN) | 225419 |
| Legal Business Name | Belmont Manor Nursing Home Inc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1245218403 |
| Organization Name | BELMONT MANOR NURSING HOME INC |
| Address | 34 Agassiz Ave, Belmont, MA 02478 |
| Phone Number | 617-489-1200 |
News Archive
Alcyone Lifesciences, Inc., a leader in neural intervention systems for neurological conditions and targeted drug delivery, and DNAtrix Inc., a privately held biotechnology company and a leader in oncolytic virus therapy, have entered into an exclusive clinical collaboration. Under the agreement, DNAtrix will utilize Alcyone's MEMS Cannula (AMC) targeted delivery platform for the intratumoral delivery of DNX-2401, an oncolytic adenovirus and DNAtrix's lead product for the treatment of the most aggressive form of brain cancer, glioblastoma (GBM).
MIT neuroscientists have shown they can influence people's moral judgments by disrupting a specific brain region - a finding that helps reveal how the brain constructs morality.
Around half of patients with idiopathic normal-pressure hydrocephalus will develop dementia, despite responding to shunting, study findings suggest.
Celldex Therapeutics, Inc. today announced that the first patient has been screened in a randomized Phase 2 study of the Company's novel, first-in-class antibody-based vaccine candidate from its Precision Targeted Immunotherapy (PTI) platform. This study will evaluate the CDX-1307 regimen in both neoadjuvant and adjuvant settings in patients with newly diagnosed muscle-invasive bladder cancers that express hCG-beta.
› Verified 1 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Alcyone Lifesciences, Inc., a leader in neural intervention systems for neurological conditions and targeted drug delivery, and DNAtrix Inc., a privately held biotechnology company and a leader in oncolytic virus therapy, have entered into an exclusive clinical collaboration. Under the agreement, DNAtrix will utilize Alcyone's MEMS Cannula (AMC) targeted delivery platform for the intratumoral delivery of DNX-2401, an oncolytic adenovirus and DNAtrix's lead product for the treatment of the most aggressive form of brain cancer, glioblastoma (GBM).
MIT neuroscientists have shown they can influence people's moral judgments by disrupting a specific brain region - a finding that helps reveal how the brain constructs morality.
Around half of patients with idiopathic normal-pressure hydrocephalus will develop dementia, despite responding to shunting, study findings suggest.
Celldex Therapeutics, Inc. today announced that the first patient has been screened in a randomized Phase 2 study of the Company's novel, first-in-class antibody-based vaccine candidate from its Precision Targeted Immunotherapy (PTI) platform. This study will evaluate the CDX-1307 regimen in both neoadjuvant and adjuvant settings in patients with newly diagnosed muscle-invasive bladder cancers that express hCG-beta.
› Verified 1 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 13.67 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 1.27 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 54.72 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 1.86 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 3.22 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 1.17 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 5.48 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 98.63 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 21.39 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 89.85 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 1.6 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 27.17 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 18.88 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 9.57 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 99.8 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 80 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 86.07 | 82.93 |
News Archive
Alcyone Lifesciences, Inc., a leader in neural intervention systems for neurological conditions and targeted drug delivery, and DNAtrix Inc., a privately held biotechnology company and a leader in oncolytic virus therapy, have entered into an exclusive clinical collaboration. Under the agreement, DNAtrix will utilize Alcyone's MEMS Cannula (AMC) targeted delivery platform for the intratumoral delivery of DNX-2401, an oncolytic adenovirus and DNAtrix's lead product for the treatment of the most aggressive form of brain cancer, glioblastoma (GBM).
MIT neuroscientists have shown they can influence people's moral judgments by disrupting a specific brain region - a finding that helps reveal how the brain constructs morality.
Around half of patients with idiopathic normal-pressure hydrocephalus will develop dementia, despite responding to shunting, study findings suggest.
Celldex Therapeutics, Inc. today announced that the first patient has been screened in a randomized Phase 2 study of the Company's novel, first-in-class antibody-based vaccine candidate from its Precision Targeted Immunotherapy (PTI) platform. This study will evaluate the CDX-1307 regimen in both neoadjuvant and adjuvant settings in patients with newly diagnosed muscle-invasive bladder cancers that express hCG-beta.
› Verified 1 days ago
Belmont Manor Nursing Home, In Location: 34 Agassiz Avenue, Belmont, Massachusetts 02478 Phone: (617) 489-1200 |